Salute e Benessere

LILYSILK's SILKERRY™ Collection Sells Out in Five Days, Signaling Strong Demand…

The sold-out collection includes three distinctive style lines: Seamflow, Porchlight, and Heirloom '89, available in four neutral colorways. Each line reflects a different facet of modern lifestyles, including city movement, relaxed home living, and timeless sportswear. Signature pieces such as the Seamflow Verge Hoodie and Heirloom '89 Zip Jacket have been praised for their elegance and functionality. The sold-out collection includes three distinctive style lines: Seamflow, Porchlight, and...
PR Newswire
29/09/2025

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead…

Under the agreement, HHP and Hanmi Pharm ("Hanmi") will grant Gilead exclusive global rights to encequidar within the field of virology. In addition, HHP and Hanmi will provide drug supply, share technical know-how, and participate as key project partners. HHP and Hanmi will each receive an upfront payment and are eligible to receive development, regulatory and sales milestones in addition to low single-digit royalties on net sales. Under the agreement, HHP andHanmi…
PR Newswire
29/09/2025

New medical writing service QInscribe reduces the time to generate a draft…

"Medical writing can benefit from the AI revolution that is reshaping industries worldwide. It can still uphold the highest quality standards that you would expect, but in a fraction of the time,"saidAmol Hule, Associate Director of Medical Writing at QInscribe."We combine specialist human insight from a team of experienced medical writers with AI-enabled efficiencies to ensure every deliverable is accurate, consistent, and submission-ready." Whereas a draft Clinical...
PR Newswire
29/09/2025

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the…

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US Basel, September 29, 2025– Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering...
Nasdaq GlobeNewswire
29/09/2025

CeraVe and L'Oréal Groupe Win Prestigious IFSCC Applied Research Award for…

"Receiving the IFSCC Applied Research Award is a testament to our joint commitment to scientific innovation and understanding the intricate biology of skin and scalp barrier health," said Gene Colón, Global Senior Vice President, Medical Affairs & Communications for CeraVe at L'Oréal. "This game-changing research moves beyond the traditional view of dandruff to highlight the role of ceramide deficiency and scalp barrier dysfunction, the critical bacterial component and the…
PR Newswire
29/09/2025

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company’s shareholders.Dear Fellow Shareholders,Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress - refining our strategy, reinforcing our operations, and positioning every business unit...
Nasdaq GlobeNewswire
29/09/2025

BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase…

Section 12 of the February 11th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31, 2024. On December 9th, 2024, Horizon and BioVaxys amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025."On May 28th, 2025, Horizon and BioVaxys further amended the APA by agreeing to delete the reference to "December 31…
PR Newswire
29/09/2025

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an…

The FDA submission is grounded in the results from the FRONTIER study program, a comprehensive program of studies designed to establish the efficacy and safety profile of denecimig as a prophylaxis treatment to prevent or reduce the frequency of bleeding episodes in people with hemophilia A, with or without inhibitors.1,3-6 The FDA submission is grounded in the results from the FRONTIER study program, a comprehensive program of studies designed to establish the efficacy and safety profile of...
PR Newswire
29/09/2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding. Such offer is being made upon...
Nasdaq GlobeNewswire
29/09/2025

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

Orascovery™ is an innovative oral drug delivery proprietary platform owned by Hanmi that enables the conversion of injectable medicines into oral formulations. Encequidar is a P-gp inhibitor that was discovered through Hanmi's Orascovery™ platform and originally developed by Hanmi. Orascovery™ is an innovative oral drug delivery proprietary platform owned by Hanmi that enables the conversion of injectable medicines into oral formulations. Encequidar is a P-gp inhibitor that was discovered...
PR Newswire
29/09/2025

Bulat Utemuratov Foundation Joins Global Autism Advocacy Coalition at the United…

The Coalition, created with the support of the World Health Organization (WHO), UNICEF, Autism Speaks, and the Qatar Foundation, will bring together international experts, policymakers, and civil society leaders to strengthen inclusion and improve the quality of life for people with autism worldwide. Its mission is to consolidate the efforts of governments, international organisations, and non-profits to promote rights, expand research, improve policy coordination, and strengthen advocacy on…
PR Newswire
29/09/2025

Mibro Expands Global Presence with GITEX Dubai 2025 Debut

Another highlight is the Mibro Kids Watch Phone Series, led by the newly launched S1. Positioned as a premium upgrade, the S1 enhances safety through advanced health monitoring capabilities. Real-time tracking of heart rate and blood oxygen levels gives parents greater peace of mind, while maintaining the fun and engaging features that have made the series popular among families. S1 represents a meaningful step forward in combining playfulness with responsibility, reflecting how technology can…
PR Newswire
29/09/2025

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation…

Each year, Frost & Sullivan presents this honor to a company that demonstrates outstanding strategy development and implementation. It celebrates forward-looking organizations that are redefining their industries through transformative innovation and growth excellence. Viva Biotech stood out in the rigorous benchmarking, excelling in both strategy effectiveness and execution. Each year, Frost & Sullivan presents this honor to a company that demonstrates outstanding strategy development…
PR Newswire
29/09/2025

OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold

Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI1fl_k2sj30Cw.png Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI1fl_k2sj30Cw.png Image: https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI2fl_68Qw97R2.png The journey began over half a century ago, with the launch of the first OMRON-branded BPM in 1973, when all blood pressure measurement was conducted at medical facilities. Nowadays, thanks...
PR Newswire
29/09/2025

Leqembi® approved for IV maintenance treatment in China

AD is a progressive, relentless disease characterized by formation of protein deposits known as plaques made of amyloid-beta aggregates and neurofibrillary tangles made of tau protein in the brains of people living with AD. It is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after plaque removal.[i],[ii],[iii],[iv] The data show that Aβ protofibrils[1] and tau tangles play roles in the neurodegeneration process,i,ii and Leqembi…
PR Newswire
29/09/2025

Inventiva reports its unaudited 2025 first-half financial results and provides a…

Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits 1as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million 2, following in particular the completion in April 2025 of enrolment of the Phase 3 clinical trial NATiV3 evaluating lanifibranor in patients with MASHCash runway currently planned until the end of the third quarter of 2026Revenues of €4.5 million...
Nasdaq GlobeNewswire
29/09/2025

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally…

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy versus placebo. 1 Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity) but did not meet their key secondary endpoint (risk of acute exacerbation, hospitalization for respiratory cause, or death)...
Nasdaq GlobeNewswire
29/09/2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a…

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDTCOPENHAGEN, Denmark; UTRECHT, The...
Nasdaq GlobeNewswire
29/09/2025

Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition…

VISUfarma's established European operations will provide market expansion opportunities, direct presence and further business diversification across major European countries, including Italy, the UK, Spain, Germany and France. In addition, VISUfarma's broad portfolio of 60+ branded ophthalmology products will present growth opportunities to accelerate Lupin's expansion into the specialty segment across regions, and is projected to drive growth in Europe as well as in other markets…
PR Newswire
29/09/2025

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation…

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Viva Biotech excelled in both, demonstrating an ability to align advanced technologies with client demand, precisely and at scale. "By integrating multimodal artificial intelligence…
PR Newswire
29/09/2025

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early…

TOKYO and CAMBRIDGE, Mass., Sept.28, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (brand name in China: “乐意保 ® ”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by...
Nasdaq GlobeNewswire
29/09/2025

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3…

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the...
Nasdaq GlobeNewswire
28/09/2025

Oculis Publishes Notification of Transactions by Person Discharging Managerial…

Attachment pdmr-notification-r-sherif-sales-sep 2025
Nasdaq GlobeNewswire
26/09/2025

Casino Group Communication

Casino Group Communication Paris, 26 September 2025On 24 September 2025 Sendas Distribuidora S.A. (“Assaí”) announced via a press release that it had submitted a request for a provisional measure requesting, among others, the unavailability of the shares ofCompanhia Brasileira de Distribuição – GPA (“GPA”)held by Casino group. This precautionary measure would have been filed ahead of the initiation of an arbitration procedure againstCasino Guichard Perrachon S.A. and Segisor...
Nasdaq GlobeNewswire
26/09/2025
Altri  Comunicati